Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12493153 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29547329 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29398074 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29552281 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29400538 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL30695566 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL119866 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL119859 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8656057 | 0.90 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL14029674 | 0.89 | MDM4 (0.48) | MDM4TP53CASP3MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114621317-B | Activatable multi-modal molecular probe for early diagnosis of prostate cancer and in-vivo longitudinal quantitative research, and preparation method and application thereof | 苏州大学 | 2022-12-30 | — | — | CN | claimed |
| CN-114621317-A | Activatable multi-modal molecular probe for early diagnosis of prostate cancer and in-vivo longitudinal quantitative research, and preparation method and application thereof | 苏州大学 | 2022-06-14 | — | — | CN | claimed |
| CN-112961173-B | Prostate specific membrane antigen targeted molecular probe, preparation method and application thereof | 江南大学附属医院 | 2022-04-19 | — | — | CN | claimed |
| US-20260137821-A1 | PEPTIDE STRUCTURE TARGETING CARBONIC DEHYDROGENASE IX AND USE THEREOF | C-BIOMEX CO., LTD. (KR) | 2026-05-21 | — | — | US | disclosed |
| US-20260139007-A1 | EPHA4 ANTAGONISTS AND USES THEREOF | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4743108-A1 | COMPOSITIONS OF PNEUMOCOCCAL ANTIGENS | Virometix AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20260117070-A1 | NEAR-INFRARED FLUORESCENT HEPTAMETHINE DYE CONJUGATES WITH FAVORABLE BLEACHING PROPERTIES | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2026-04-30 | — | — | US | disclosed |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| EP-3604326-B1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM CORP (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2026-01-01 | — | — | US | disclosed |
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2022-06-09 | — | — | US | disclosed |
| CN-111690041-B | Polypeptide with anti-tumor activity and preparation method thereof | 上海大学 | 2022-06-07 | — | — | CN | disclosed |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | FUJIFILM CORPORATION (JP) | 2022-05-03 | — | — | US | disclosed |
| CN-107108698-B | Macrocyclic peptides as immunomodulators | 百时美施贵宝公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022084486-A1 | SELF-PURIFIED NUCLEIC ACID ENCODED LIBRARIES | ETH ZURICH (CH) | 2022-04-28 | — | — | WO | disclosed |
| CN-112961173-B | Prostate specific membrane antigen targeted molecular probe, preparation method and application thereof | 江南大学附属医院 | 2022-04-19 | — | — | CN | disclosed |
| US-20220090189-A1 | POLYPEPTIDE TAGGED NUCLEOTIDES AND USE THEREOF IN NUCLEIC ACID SEQUENCING BY NANOPORE DETECTION | Roche Sequencing Solutions, Inc. (US) | 2022-03-24 | — | — | US | disclosed |
| CN-108350017-B | Polypeptide-labeled nucleotides and their use in nucleic acid sequencing by nanopore detection | 豪夫迈·罗氏有限公司 | 2022-03-15 | — | — | CN | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220090189-A1 | POLYPEPTIDE TAGGED NUCLEOTIDES AND USE THEREOF IN NUCLEIC ACID SEQUENCING BY NANOPORE DETECTION | NPPA, ANPEP, TENT4A | MDM4 1047/4885TP53 447/4885CASP3 4383/4885 |
| US-20260117070-A1 | NEAR-INFRARED FLUORESCENT HEPTAMETHINE DYE CONJUGATES WITH FAVORABLE BLEACHING PROPERTIES | CBR1, CBR3, NR2E3 | MDM4 4448/4885TP53 4160/4885CASP3 466/4885 |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 3040/4885TP53 421/4885CASP3 1560/4885 |
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | SLC10A1, CD47, SELPLG | MDM4 4667/4885TP53 1471/4885CASP3 2354/4885 |
| US-20260137821-A1 | PEPTIDE STRUCTURE TARGETING CARBONIC DEHYDROGENASE IX AND USE THEREOF | CA5A, CA1, CA9 | MDM4 4329/4885TP53 2780/4885CASP3 2512/4885 |
| US-20260139007-A1 | EPHA4 ANTAGONISTS AND USES THEREOF | EPHA4, EPHA1, EPHB4 | MDM4 2075/4885TP53 1662/4885CASP3 4081/4885 |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | VIP, NPPA, NGLY1 | MDM4 4154/4885TP53 1409/4885CASP3 2306/4885 |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | MDM4 3948/4885TP53 1042/4885CASP3 474/4885 |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | DDX21, PHAX, RBX1 | MDM4 2407/4885TP53 2772/4885CASP3 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.